Find disease awareness content and relevant supporting materials

This European consensus guideline updates diagnostic recommendations for cutaneous melanoma. It covers dermoscopy, imaging, mutation testing, and stage-based follow-up strategies to improve early detection and patient outcomes.

Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape...

The SEOM-GEM guidelines address the rising incidence of cutaneous melanoma and emphasize early diagnosis and timely treatment. They provide evidence-based recommendations for adjuvant and neoadjuvant therapies, advanced disease management, and follow-up strategies, including special cases like brain metastases.

Pembrolizumab is an approved first-line systemic therapy for unresectable metastatic melanoma. Despite the achievement of complete and durable responses in a small subgroup of patients, it is standard practice that ...

The introduction of BRAF and MEK inhibitors into clinical practice improved the prognosis of metastatic melanoma patients. The combination of BRAF inhibitor dabrafenib with MEK inhibitor trametinib has shown...

This European guideline update details treatment strategies for cutaneous melanoma, including surgical margins, sentinel lymph node biopsy, and systemic therapies. It covers adjuvant and neoadjuvant immunotherapy, targeted therapy for BRAFV600 mutations, and recommendations for advanced disease management.

Detection and removal of melanoma, before it has metastasized, dramatically improves prognosis and survival.

Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.

We sought to determine whether adjuvant dabrafenib plus trametinib would improve outcomes in patients with resected, stage III melanoma with BRAF V600 mutations.

Background: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma.